Tofacitinib citrate

DRUG5 trials

Sponsors

Pfizer Inc., Tufts Medical Center, TWi Biotechnology, Inc., CAGE Bio Inc.

Conditions

Atopic DermatitisDiscoid Lupus ErythematosusHealthy SubjectsJuvenile Idiopathic Arthritis (JIA)Systemic Lupus ErythematosusUlcerative Colitis (UC)

Early Phase 1

Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

TerminatedNCT03159936

Tufts Medical CenterDiscoid Lupus Erythematosus, Systemic Lupus Erythematosus

Start: 2017-04-03End: 2020-06-10Updated: 2022-01-21

Phase 1

Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study

CompletedNCT04468425

TWi Biotechnology, Inc.Healthy Subjects

Start: 2020-10-14End: 2020-12-21Updated: 2021-11-29

Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis

CompletedNCT05487963

CAGE Bio Inc.Atopic Dermatitis

Start: 2022-11-09End: 2023-07-30Updated: 2025-02-13

Phase 2

A3921145 - A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)

CompletedCTIS2023-509651-14-00

Pfizer Inc.Juvenile Idiopathic Arthritis (JIA)

Start: 2013-04-03End: 2024-12-18Target: 8Updated: 2025-01-21

Phase 3

A3921210 - OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

RecruitingCTIS2023-509694-22-00

Pfizer Inc.Ulcerative Colitis (UC)

Start: 2022-01-26Target: 37Updated: 2025-09-01